Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica

Drugs Aging. 2019 Nov;36(11):1015-1026. doi: 10.1007/s40266-019-00705-5.

Abstract

Polymyalgia rheumatica is an inflammatory rheumatic disease of the elderly characterised by pain and stiffness in the neck and pelvic girdle, and is the second most common inflammatory rheumatic condition in this age group, after rheumatoid arthritis. Polymyalgia rheumatica can occur independently or in association with giant cell arteritis, which is the most common form of primary vasculitis. The diagnosis of polymyalgia rheumatica is usually based on clinical presentation and increase of inflammatory markers. There are no pathognomonic findings that can confirm the diagnosis. However, different imaging techniques, especially ultrasonography, can assist in the identification of polymyalgia rheumatica. Glucocorticoids are the cornerstone of the treatment of polymyalgia rheumatica, but they might be associated with different adverse events. A subgroup of patients presents with a refractory disease course and, in these cases, adding methotrexate as a steroid-sparing agent could be useful. In this review, we summarise the latest findings regarding the pathogenesis, diagnosis and management of polymyalgia rheumatica and try to highlight the possible pitfalls, especially in elderly patients.

Publication types

  • Review

MeSH terms

  • Aged
  • Antirheumatic Agents / therapeutic use*
  • Biological Products / therapeutic use*
  • Diagnosis, Differential
  • Giant Cell Arteritis* / diagnosis
  • Giant Cell Arteritis* / drug therapy
  • Giant Cell Arteritis* / etiology
  • Glucocorticoids / therapeutic use*
  • Humans
  • Polymyalgia Rheumatica* / diagnosis
  • Polymyalgia Rheumatica* / drug therapy
  • Polymyalgia Rheumatica* / etiology

Substances

  • Antirheumatic Agents
  • Biological Products
  • Glucocorticoids